Archimedes Pharma has acquired Link Pharmaceuticals of Horsham, West Sussex, for almost £25m. Link is a profitable business which is on track to record revenues of around £16 million in 2006, showing steady growth. Link will become the UK commercial organisation for Archimedes whilst the French and German operations will form the basis of Archimedes’ European commercial operations.  Other financial terms were not disclosed. Archimedes was launched in 2004, with the backing of Warburg Pincus. The company’s strategy is to grow its commercial operations through acquisition and partnering and to advance its development pipeline, including its lead product, Nasalfent™, which could reach the market in 2009. The acquisition of Link brings Archimedes a commercial infrastructure of around 40 people to add to its existing organisation. The current customer base targeted by Link are some of the future prescribers for Archimedes’ late stage portfolio, including the phase III product, Nasalfent™, intranasal fentanyl for rapid relief of breakthrough cancer pain.